Table. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from the World Health Organization EGASP, Cambodia, 2022–2023*.
| Antimicrobial drug | 2022, n = 76, no. (%) (2) | 2023, n = 72, no. (%) |
|---|---|---|
| Ceftriaxone >0.125 μg/mL† | 29 (38) | 22 (31) |
| Cefixime >0.25 μg/mL† | 29 (38) | 22 (31) |
| Azithromycin >2.0 μg/mL† | 0 | 1 (1.4) |
| Azithromycin >256 μg/mL† | 3 (4) | 9 (12.5) |
| Ciprofloxacin resistant >1 μg/mL‡ | 74 (97) | 70 (97) |
| Penicillin resistant >2 μg/mL‡ | 71 (93) | 59 (82) |
| Spectinomycin resistant >128 μg/mL‡ | 0 | 0 |
*EGASP, Enhanced Gonococcal Antimicrobial Surveillance Programme. †The Clinical Laboratory Standards Institute criteria for resistance to ceftriaxone, cefixime, and azithromycin have not been established. The EGASP MIC alert value criteria were ceftriaxone, MIC >0.125 μg/mL; cefixime, MIC >0.25 μg/mL; azithromycin, MIC >2.0 μg/mL; and azithromycin, MIC >256 μg/mL. ‡Antimicrobial susceptibility criteria established by the Clinical Laboratory Standards Institute (https://www.clsi.org) were used to determine resistance to the antibiotics tested in the EGASP for ciprofloxacin, penicillin, and spectinomycin.